Electric
cell-substrate impedance sensing (ECIS) is an innovative
approach for the label-free and real-time detection of cell morphology,
growth, and apoptosis, thereby playing an essential role as both a
viable alternative and valuable complement to conventional biochemical/pharmaceutical
analysis in the field of diagnostics. Constant improvements are naturally
sought to further improve the effective range and reliability of this
technology. In this study, we developed poly(3,4-ethylenedioxythiophene)-poly(styrenesulfonate)
(PEDOT:PSS) conducting polymer (CP)-based bioelectrodes integrated
into homemade ECIS cell-culture chamber slides for the simultaneous
drug release and real-time biosensing of cancer cell viability under
drug treatment. The CP comprised tailored PEDOT:PSS, poly(ethylene
oxide) (PEO), and (3-glycidyloxypropyl)trimethoxysilane (GOPS) capable
of encapsulating antitumor chemotherapeutic agents such as doxorubicin
(DOX), docetaxel (DTX), and a DOX/DTX combination. This device can
reliably monitor impedance signal changes correlated with cell viability
on chips generated by cell adhesion onto a predetermined CP-based
working electrode while simultaneously exhibiting excellent properties
for both drug encapsulation and on-demand release from another CP-based
counter electrode under electrical stimulation (ES) operation. Cyclic
voltammetry curves and surface profile data of different CP-based
coatings (without or with drugs) were used to analyze the changes
in charge capacity and thickness, respectively, thereby further revealing
the correlation between their drug-releasing performance under ES
operation (determined using ultraviolet–visible (UV–vis)
spectroscopy). Finally, antitumor drug screening tests (DOX, DTX,
and DOX/DTX combination) were performed on MCF-7 and HeLa cells using
our developed CP-based ECIS chip system to monitor the impedance signal
changes and their related cell viability results